



## **GNCC CAPITAL, INC.**

**COMPANY PROVIDES AN UPDATE AS TO ACTIONS  
BEING UNDERTAKEN THIS COMING WEEK**

**MARCH 3, 2019**

The Current Board of Directors of GNCC Capital, Inc.\* (“GNCC” or “the Company”), quoted on the OTC Markets under the Trading Symbol “GNCP” confirm that;

\*The Current Directors depart the GNCC Board of Directors on or before March 31, 2019 (close of the Transition Period).

During the Transition Period, the Current Directors will:

- a) Ensure that all outstanding Quarterly and Annual Reports are completed and filed to restore the Company to a “CURRENT FILER” and on the OTC Markets; and
- b) Deal with the Company’s Mining Exploration Interests and cancel all issued and outstanding shares of secured Classes of Preferred Common Stock; and
- c) Only issue Press Releases that pertain to (a) and (b) as above-mentioned.

During the Transition Period, the BioCann Pharma Group Management will:

- a) Introduce and familiarize the GNCC Shareholders and Investors to their business, its prospects, their Management and all other pertinent information. This they will do through Press Releases\*; and
- b) Complete the necessary web sites to better explain their business; and
- c) Appoint (one) Director to the Board of GNCC during this coming week.

\*To best explain the “communication process” and timing of Press Releases, we summarize as follows:

BioCann Pharma is a part of a large organization which is interlinked with “overlapping Management functions”, Partnerships as well as direct and indirect Joint Venture Agreements in the Republic of Colombia. Their primary Partner Company operates in other Countries in addition to the Republic of Colombia. The BioCann Pharma Group Executives operate primarily from two areas in the Republic of Colombia as well in Ontario, Canada; certain other key Executives are based in three additional countries.

The new GNCC Board of Directors on March 31, 2019 will be comprised of BioCann Pharma Group Executives as well Executives from their Partnerships and Joint Ventures.

Given the various time zones between your Current Directors being in Johannesburg, South Africa, BioCann Pharma Group Executives travelling and being based in different time zones, “mutually agreed upon” Press Releases are taking as long as 3 (Three) business days to be drafted, facts and statements verified and then approved by all of the parties.

### ACTIONS BEING UNDERTAKEN THIS WEEK:

Following discussions with BioCann Pharma Group and their Head of Corporate Finance, your Current Directors can now confirm that during this week, shareholders should expect the following:

- i) The first BioCann Pharma Group Executive being appointed to the GNCC Board; and
- ii) No less than 2 (Two) initial detailed Press Releases prepared by BioCann Pharma Group and verified and approved by the Current Directors of GNCC; being published.
- iii) The Current Directors cannot possibly issue a BioCann Press Release tomorrow, Monday March 3, 2019; solely due to time differences and travel schedules. We only mention this as a number of shareholders appear to be expecting a Press Release tomorrow.

### FINALLY:

As always, your Current Directors strongly urge shareholders to reach out to us for facts; wild speculation coupled with false and/or misleading information being posted on Internet Stock Forums; is honestly just that. Shareholders should base their investment and/or trading decisions solely upon BioCann Pharma Group Management commentary.

**DATED: MARCH 3, 2019**

**RONALD YADIN LOWENTHAL**  
**GNCC CAPITAL, INC.**  
**EXECUTIVE CHAIRMAN**

**NICOLAAS EDWARD BLOM**  
**GNCC CAPITAL, INC.**  
**PRESIDENT & CHIEF OPERATING OFFICER**